Meine Merkliste
my.bionity.com  
Login  

Non-Small Cell Lung Cancer – Pipeline Review, H1 2012

Introduction

Global Markets Direct’s, 'Non-Small Cell Lung Cancer - Pipeline Review, H1 2012', provides an overview of the Non-Small Cell Lung Cancer therapeutic pipeline. This report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. 'Non-Small Cell Lung Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
- A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Highlights

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Non-Small Cell Lung Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Pharma / Arzneimittel   Marktstudie
Jahrgang:   2012
Herausgeber:   Global Markets Direct
Preis:   500.00€
Mehr über Global Markets Direct
  • Marktstudien

    Chile ENT Devices Investment Opportunities, Analysis and Forecasts to 2018

    Introduction ”Chile ENT Devices Investment Opportunities, Analysis and Forecasts to 2018”, a new report by Global Markets Direct, provides key market data on the Chile ENT Devices market. The report provides value (USD million), volume (units) and average price (USD) data for each segment ... mehr

    Hemophilia – Pipeline Review, H1 2012

    Introduction Global Markets Direct’s, 'Hemophilia - Pipeline Review, H1 2012', provides an overview of the Hemophilia therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and ... mehr

    Schizophrenia – Pipeline Review, H1 2012

    Introduction Global Markets Direct’s, 'Schizophrenia - Pipeline Review, H1 2012', provides an overview of the Schizophrenia therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late-s ... mehr

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.